Development and Optimisation of Hepatitis B Recombinant Antigen Loaded Chitosan Nanoparticles As an Adjuvant Using the Response Surface Methodology

Development and Optimisation of Hepatitis B Recombinant Antigen Loaded Chitosan Nanoparticles As an Adjuvant Using the Response Surface Methodology Publisher

Mehrabi M¹ ; Sadeghisoureh S² ; Dounighi NM³ ; Rezayat SM^{4, 5} ; Doroud D⁶ ; Khoobi M⁷ ; Amani A⁴

Show Affiliations

1. Department of Medical Nanotechnology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran
2. Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran
3. Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran
4. Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
5. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
6. Regulatory Department, Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran
7. Biomaterials Group, Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran

Source: Micro and Nano Letters Published:2020

Abstract

The main purpose of this Letter was to develop and optimise recombinant hepatitis B antigen-loaded chitosan nanoparticles (rHBsAg-CS NPs) as a new adjuvant for hepatitis B vaccine through designing by response surface methodology (RSM). The NPs were prepared by employing ionic gelation technique. RSM was utilised by selecting the independent variablesincluding the concentration of CS, tripolyphosphate and antigen concentration as well as pH and homogenisation speed to obtain maximum encapsulation efficiency (EE) and loading capacity (LC). EE and LC of the optimised preparation were 93.2 ± 1.1 and 25.6 ± 1.38%, respectively. Optimised NPs showed spherical shape, particle size of 187 ± 14 nm and positive zeta potential (+31.3 ± 1.5 mV). In vitro release profile of optimised formulation revealed an initial burst, followed by a slow sustained antigen release. Cell viability assay indicated that the toxicity of NPs was concentrationdependent. SDS-PAGE analysis confirmed the structural stability and integrity of the released antigen. ELISA and Ouchterlony double immunodiffusion tests of released antigen showed that the antigenicity was preserved during the process of NP formation. © 2020 Institution of Engineering and Technology. All rights reserved.

2. Novel Approach to Improve Vaccine Immunogenicity: Mannosylated Chitosan Nanoparticles Loaded With Recombinant Hepatitis B Antigen As a Targeted Vaccine Delivery System, Journal of Drug Delivery Science and Technology (2018)

3. Therapeutic Application of Nanoparticles in Hepatitis Diseases: A Narrative Review (2011-2021), Current Pharmaceutical Biotechnology (2023)

4. In Vitro Evaluation of Zeolite-Nha Blended Pcl/Pla Nanofibers for Dental Tissue Engineering, Materials Chemistry and Physics (2020)

5. Immunogenicity of Different Types of Adjuvants and Nano-Adjuvants in Veterinary Vaccines: A Comprehensive Review, Vaccines (2023)

6. Immune Responses of Mice Immunized With Hbsag Formulated in Naloxone/Alum Mixture: Comparison to Fendrix Vaccine, Hepatitis Monthly (2017)

7. Evaluation of G2 Citric Acid-Based Dendrimer As an Adjuvant in Veterinary Rabies Vaccine, Viral Immunology (2018)

8. Processing of Liposome-Encapsulated Natural Herbs Derived From Silybum Marianum Plants for the Treatment of Breast Cancer Cells, Scientia Iranica (2022)

Experts (# of related papers)

View all Related Experts

Seyed Mahdi Rezayat Sorkhabadi (2)

Mehdi Khoobi (2)

Style	Citing Format
MLA	Mehrabi M, et al.. "Development and Optimisation of Hepatitis B Recombinant Antigen Loaded Chitosan Nanoparticles As an Adjuvant Using the Response Surface Methodology." Micro and Nano Letters, vol. 15, no. 11, 2020, pp. 736-741.
APA	Mehrabi M, Sadeghisoureh S, Dounighi NM, Rezayat SM, Doroud D, Khoobi M, Amani A (2020). Development and Optimisation of Hepatitis B Recombinant Antigen Loaded Chitosan Nanoparticles As an Adjuvant Using the Response Surface Methodology. Micro and Nano Letters, 15(11), 736-741.
Chicago	Mehrabi M, Sadeghisoureh S, Dounighi NM, Rezayat SM, Doroud D, Khoobi M, Amani A. "Development and Optimisation of Hepatitis B Recombinant Antigen Loaded Chitosan Nanoparticles As an Adjuvant Using the Response Surface Methodology." Micro and Nano Letters 15, no. 11 (2020): 736-741.
Harvard	Mehrabi M et al. (2020) 'Development and Optimisation of Hepatitis B Recombinant Antigen Loaded Chitosan Nanoparticles As an Adjuvant Using the Response Surface Methodology', Micro and Nano Letters, 15(11), pp. 736-741.
Vancouver	Mehrabi M, Sadeghisoureh S, Dounighi NM, Rezayat SM, Doroud D, Khoobi M, et al.. Development and Optimisation of Hepatitis B Recombinant Antigen Loaded Chitosan Nanoparticles As an Adjuvant Using the Response Surface Methodology. Micro and Nano Letters. 2020;15(11):736-741.
BibTex	@article{ author = {Mehrabi M and Sadeghisoureh S and Dounighi NM and Rezayat SM and Doroud D and Khoobi M and Amani A}, title = {Development and Optimisation of Hepatitis B Recombinant Antigen Loaded Chitosan Nanoparticles As an Adjuvant Using the Response Surface Methodology}, journal = {Micro and Nano Letters}, volume = {15}, number = {11}, pages = {736-741}, year = {2020} }
RIS	TY - JOUR AU - Mehrabi M AU - Sadeghisoureh S AU - Dounighi NM AU - Rezayat SM AU - Doroud D AU - Khoobi M AU - Amani A TI - Development and Optimisation of Hepatitis B Recombinant Antigen Loaded Chitosan Nanoparticles As an Adjuvant Using the Response Surface Methodology JO - Micro and Nano Letters VL - 15 IS - 11 SP - 736 EP - 741 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract